NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SynuCa Therapeutics

SynuCa Therapeutics

Private
CopenhagenHealthcare & Life Scienceshttps://www.synuca.com/

Last Round

Follow-on Offering

Mar 2, 2026

Total Funding Raised

$2.01M

Company Overview

SynuCa Therapeutics is a drug discovery company that develops small molecule therapies intended to address Parkinson's disease and other neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

disease-modifying therapysmall molecule therapyParkinson's diseasesynucleinopathyneurodegenerative diseasecalcium modulatordrug discoverybiotech R&DSERCA targetpreclinical biotechcalcium imbalancepharma licensingfirst-in-class therapyalpha-synuclein

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynuCa Therapeutics Comparables

Compare SynuCa Therapeutics with similar companies based on industry and business-model similarity.

SynuCa Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Teitur Trophics
71%
Mission Therapeutics
70%
Gain Therapeutics Inc
69%

SynuCa Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Follow-on OfferingMar 2, 2026
AcceleratorFeb 25, 2025

Key People

Founding team and executive leadership

Lasse Reimer

Chief Executive Officer

Executive Team

William Dalby-Brown

Chief Operating Officer, SynuCa Therapeutics ApS

Executive Team

SynuCa Therapeutics Investors

Notable investors and investment history

SynuCa Therapeutics investors
InvestorRounds
BioInnovation InstituteFollow-on Offering, Accelerator
NOMEAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 25, 2025

    $520K raised from BioInnovation Institute and NOME.

SynuCa Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SynuCa Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SynuCa Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range2
Year Founded2025
Last FundingMar 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.